# TLR9 Immunotherapy for Peritoneal Carcinomatosis

> **NCT07658196** · PHASE1 · RECRUITING · sponsor: **Brown University** · enrollment: 24 (estimated)

## Conditions studied

- Malignant Ascites
- Colorectal Adenocarcinoma
- Peritoneal (Metastatic) Cancer
- Appendiceal Adenocarcinoma

## Interventions

- **DRUG:** ACM-CpG

## Key facts

- **NCT ID:** NCT07658196
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2028-07
- **Final completion:** 2030-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658196, "TLR9 Immunotherapy for Peritoneal Carcinomatosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*